Sanofi(US:SNY)2025-10-24 12:30Financial Performance - Q3 2025 sales reached €12434 billion, a 7% increase at CER (constant exchange rates)[17, 51] - Dupixent sales exceeded €4 billion for the first time in a quarter, growing by 262%[17, 25] - Pharma launches contributed 15% of sales, totaling €1805 million, a 408% increase at CER[21, 22] - Vaccines sales decreased by 78% to €1525 billion, impacted by lower influenza sales[17, 30] - Business EPS increased by 132%, reflecting operating income growth and share buyback[56] Pipeline Highlights - Wayrilz was approved for ITP (Immune Thrombocytopenia) in the US[69, 70] - Amlitelimab met primary endpoints in the AD (Atopic Dermatitis) phase 3 study[69, 77] - Fluzone HD met the primary endpoint in the influenza 50 years+ phase 3 study[69] 2025 Outlook - The company anticipates a mid-teens percentage decline in Flu vaccines sales for full-year 2025[59] - The company expects divestments of other medicines to impact sales by approximately €200 million[59] - The company anticipates capital gains from divestments of approximately €500 million[60]